Trial Profile
The evaluation of theraputic effects for advanced renal cell carcinoma patients using axitinib; dose intensity, gene polymorphism and micro vascular density
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 01 Feb 2013 New trial record